



November 9, 2015

Mr. Sebastian Bednarczyk
Senior Adviser, Listings Compliance
ASX Compliance Pty Limited
ABN 26 087 780 489
Level 40, Central Park
152-158 St. George's Terrace
Perth WA 6000

Dear Mr. Bednarczyk:

Thank you for your letter dated November 5, 2015.

In response to the questions raised in your letter, Unilife Corporation respectfully submits the following responses:

1. Yes
2. Not applicable
3. On October 30, 2015
4. We did not make an announcement prior to November 5, 2015 because the Customer 2015 Agreement contains confidential, material, non-public information belonging to our customer, and we needed our customer's approval of the specific details to be released so as not to violate US Securities and Exchange Commission rules, including Section (10)(b) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder. We expressed our ASX obligations to our customer and the need to disclose this information in a prompt manner. As soon as our customer gave us approval to disclose the press release details we made such disclosure, and accordingly did so in compliance with Section (10)(b) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder.

I would be pleased to provide any additional information that would be helpful to your office.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "JCR", written over a horizontal line.

John C. Ryan
Senior Vice President, General Counsel & Secretary

Unilife Corporation

150 South Warner Road, King of Prussia, PA 19406 T + 1 717 384 3400 E john.ryan@unilife.com W www.unilife.com



5 November 2015

Jeff Carter
Unilife Corporation
Level 11, 1 Chifley Square
SYDNEY NSW 2000

Dear Mr Carter

UNILIFE CORPORATION (the "Entity"): ASX aware query

ASX Limited ("ASX") refers to the following:

1. The Entity's announcement entitled 5 November 2015 lodged with ASX Market Announcements Platform and released at 10:02 am AEDT on Thursday, 5 November 2015 (the "Announcement"), disclosing the execution of a supply agreement with MedImmune on 30 October 2015 ("MedImmune 2015 Agreement").
2. Listing Rule 3.1, which requires a listed entity to give ASX immediately any information concerning it that a reasonable person would expect to have a material effect on the price or value of the entity's securities.
3. The definition of "aware" in Chapter 19 of the Listing Rules. This definition states that:

"an entity becomes aware of information if, and as soon as, an officer of the entity (or, in the case of a trust, an officer of the responsible entity) has, or ought reasonably to have, come into possession of the information in the course of the performance of their duties as an officer of that entity."

Additionally, you should refer to section 4.4 in Guidance Note 8 *Continuous Disclosure: Listing Rules 3.1 – 3.1B* "When does an entity become aware of information".

4. Listing Rule 3.1A, which sets out exceptions from the requirement to make immediate disclosure, provided that each of the following are satisfied.

"3.1A Listing rule 3.1 does not apply to particular information while each of the following requirements is satisfied in relation to the information:

3.1A.1 One or more of the following applies:

- *It would be a breach of a law to disclose the information;*
- *The information concerns an incomplete proposal or negotiation;*
- *The information comprises matters of supposition or is insufficiently definite to warrant disclosure;*
- *The information is generated for the internal management purposes of the entity; or*
- *The information is a trade secret; and*



3.1A.2 *The information is confidential and ASX has not formed the view that the information has ceased to be confidential; and*

3.1A.3 *A reasonable person would not expect the information to be disclosed."*

5. ASX's policy position on the concept of "confidentiality" which is detailed in section 5.8 of Guidance Note 8 *Continuous Disclosure: Listing Rules 3.1 – 3.1B* "Listing Rule 3.1A.2 – the requirement for information to be confidential". In particular, the Guidance Note states that:

"Whether information has the quality of being confidential is a question of fact, not one of the intention or desire of the listed entity. Accordingly, even though an entity may consider information to be confidential and its disclosure to be a breach of confidence, if it is in fact disclosed by those who know it, then it ceases to be confidential information for the purposes of this rule."

Having regard to the above, we ask that you answer the following questions in a format suitable for release to the market in accordance with Listing Rule 18.7A:

1. Does the Entity consider the execution of the MedImmune 2015 Agreement to be information that a reasonable person would expect to have a material effect on the price or value of its securities?
2. If the answer to question 1 is "no", please advise the basis for that view.
3. If the answer to question 1 is "yes", when did the Entity first become aware of the execution of the MedImmune 2015 Agreement?
4. If the answer to question 1 is "yes" and the Entity first became aware of the execution of the MedImmune 2015 Agreement before the 5 November 2015, did the Entity make any announcement prior to 5 November 2015 which disclosed the execution of the MedImmune 2015 Agreement? If so, please provide details. If not, please explain why this information was not released to the market at an earlier time, commenting specifically on when you believe the entity was obliged to release the details of the MedImmune 2015 Agreement, in particular the execution of the MedImmune 2015 Agreement, under Listing Rules 3.1 and 3.1A and what steps the Entity took to ensure that the information was released promptly and without delay.
5. Please confirm that the Entity is in compliance with the Listing Rules and, in particular, Listing Rule 3.1.

When and where to send your response

This request is made under, and in accordance with, Listing Rule 18.7. Your response is required as soon as reasonably possible and, in any event, by not later than **5.30 pm (WST) on Monday, 9 November 2015**. If we do not have your response by then, ASX will have no choice but to consider suspending trading in the Entity's securities under Listing Rule 17.3.

You should note that if the information requested by this letter is information required to be given to ASX under Listing Rule 3.1 and it does not fall within the exceptions mentioned in Listing Rule 3.1A, the Entity's obligation is to disclose the information "immediately". This may require the information to be disclosed before the deadline set out in the previous paragraph.



ASX reserves the right to release a copy of this letter and your response on the ASX Market Announcements Platform under Listing Rule 18.7A. Accordingly, your response should be in a form suitable for release to the market.

Your response should be sent to me by e-mail at allexchperth@asx.com.au. It should not be sent directly to the ASX Market Announcements Office. This is to allow me to review your response to confirm that it is in a form appropriate for release to the market, before it is published on the ASX Market Announcements Platform.

Listing Rule 3.1

Listing Rule 3.1 requires a listed entity to give ASX immediately any information concerning it that a reasonable person would expect to have a material effect on the price or value of the entity's securities. Exceptions to this requirement are set out in Listing Rule 3.1A.

The obligation of the Entity to disclose information under Listing Rules 3.1 and 3.1A is not confined to, nor is it necessarily satisfied by, answering the questions set out in this letter.

In responding to this letter, you should have regard to the Entity's obligations under Listing Rules 3.1 and 3.1A and also to Guidance Note 8 *Continuous Disclosure: Listing Rules 3.1 – 3.1B*.

Trading halt

If you are unable to respond to this letter by the time specified above, you should discuss with us whether it is appropriate to request a trading halt in the Entity's securities under Listing Rule 17.1.

If you wish a trading halt, you must tell us:

- the reasons for the trading halt;
- how long you want the trading halt to last;
- the event you expect to happen that will end the trading halt;
- that you are not aware of any reason why the trading halt should not be granted; and
- any other information necessary to inform the market about the trading halt, or that we ask for.

We may require the request for a trading halt to be in writing. The trading halt cannot extend past the commencement of normal trading on the second day after the day on which it is granted.

You can find further information about trading halts in Guidance Note 16 *Trading Halts & Voluntary Suspensions*.



If you have any queries or concerns about any of the above, please contact me immediately.

Yours sincerely

[Sent electronically without signature]

Sebastian Bednarczyk

Senior Adviser, Listings Compliance